Compass Pathways PLC ADR CMPS
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
News
-
Compass Pathways Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
-
Compass Pathways Elects Kathleen Tregoning to Board of Directors
-
Compass Pathways to Participate in Jefferies Global Healthcare Conference on June 3, 2026
-
Compass Pathways to Participate in RBC Capital Markets Global Healthcare Conference on May 19-20, 2026
-
Compass Pathways Announces First Quarter 2026 Financial Results and Business Highlights
-
Compass Pathways to Announce First Quarter 2026 Financial Results on May 13, 2026
-
Compass Pathways Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
-
Compass Pathways Announces FDA Granted NDA Rolling Review Request and Awarded Commissioner's National Priority Voucher
Trading Information
- Previous Close Price
- $11.94
- Day Range
- $11.97–12.50
- 52-Week Range
- $2.25–14.75
- Bid/Ask
- $12.40 / $12.46
- Shares Outstanding
- 134.95M
- Market Cap
- $1.67B
- Volume/Avg
- 2M / 4M
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- —
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Total Yield
- —
Company Profile
Compass Pathways PLC is a biotechnology company focused on developing therapies for mental health conditions. Its research centers on a proprietary synthetic psilocybin formulation, COMP360, which is administered alongside psychological support. The company is conducting clinical trials to evaluate the safety and efficacy of this treatment in patients with treatment-resistant depression and other mental health disorders. The company operates in one operating segment.
- Sector
- Healthcare
- Industry
- Medical Care Facilities
- Stock Style Box
- —
- Total Number of Employees
- 156
- Website
- https://compasspathways.com
Valuation
|
Metric
|
CMPS
|
|---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | 4.99 |
Price/Sales | — |
Price/Cash Flow | — |
Price/Earnings
No chart available
Financial Strength
|
Metric
|
CMPS
|
|---|---|
Quick Ratio | 3.13 |
Current Ratio | 3.32 |
Interest Coverage | −37.87 |
Quick Ratio
CMPS
Profitability
|
Metric
|
CMPS
|
|---|---|
Return on Assets (Normalized) | −48.59% |
Return on Equity (Normalized) | −116.89% |
Return on Invested Capital (Normalized) | −92.31% |
Return on Assets
CMPS
Medical Care Facilities Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| HCA Healthcare Inc
HCA
| Ljfpwntr | Zgrpl | $86B | |||
| Fresenius SE & Co KGaA ADR
FSNUY
| — | Nkrgv | $26B | |||
| IHH Healthcare Bhd
IHHHF
| — | Fndjl | $19B | |||
| Tenet Healthcare Corp
THC
| Ldprbfrh | Nvqmj | $15B | |||
| DaVita Inc
DVA
| Rvtxlnl | Tqszvsp | $14B | |||
| Fresenius Medical Care AG
FMCQF
| — | Dqwlgw | $13B | |||
| Fresenius Medical Care AG ADR
FMS
| Rwdxxmxd | Fvgdgm | $13B | |||
| Encompass Health Corp
EHC
| — | Txnhby | $10B | |||
| Universal Health Services Inc Class B
UHS
| Hbyfxpxrk | Fsxqfs | $9B | |||
| Genesis Healthcare Inc Class A
GENNQ
| Rlgq | Hlmxf | $12,220 |
United States